Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Cuts Combunox Detailing Following Disappointing Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Forest plans to reassign the combination pain therapy’s 1,100-person sales force to detail Lexapro, Namenda and the launch of nebivolol, pending FDA approval.

You may also be interested in...



Mylan Finds Its Way Out Of The Woods: Forest Signs Nebivolol Licensing Agreement

Forest will assume development, sales and marketing rights for Mylan's beta blocker.

Combunox's Future At Forest May Depend On Success Of New Trial Program

The future of Forest's combination pain therapy Combunox (oxycodone/ibuprofen)could depend on the success of a new product trial program launched in late September, the company suggested

NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination

Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel